Confo Therapeutics

Confo Therapeutics is a Belgian clinical-stage biotech pioneering a unique approach to drug discovery for GPCRs, a historically challenging but highly druggable target class. The company's proprietary platform enables the development of both small molecules and antibodies, with a pipeline focused on metabolic and endocrine conditions, including neuropathic pain, obesity, and post-bariatric hypoglycemia. Backed by a €60M Series B financing and strategic partnerships, Confo is advancing its lead candidate, CFTX-1554, into Phase 1 while expanding its early-stage pipeline. The company operates as a private, pre-revenue entity leveraging its technology for internal programs and potential collaborations.

Proprietary platform using conformation-stabilizing VHH antibodies (nanobodies) to lock GPCRs in active states, enabling discovery of small molecule and antibody-based therapeutics against Class A and B GPCRs.

In neuropathic pain, Confo competes against other non-opioid developers and generic neuromodulators. In obesity, the landscape is dominated by large players (e.g., Novo Nordisk, Eli Lilly) with advanced GLP-1 and multi-agonist programs, setting a high bar for efficacy and development speed. Confo's differentiation lies in its unique platform enabling antibody discovery against GPCRs, a modality less explored in this target class.